CAS 144598-75-4 | 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl- | CAS Number 144598-75-4

Title	Journal
Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals.	Chemical research in toxicology 20170515
Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.	JAMA psychiatry 20150801
Relationship between inflammation and metabolic syndrome following treatment with paliperidone for schizophrenia.	Progress in neuro-psychopharmacology & biological psychiatry 20121203
Paliperidone extended release: in adolescents with schizophrenia.	Paediatric drugs 20121201
An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.	Drug metabolism and disposition: the biological fate of chemicals 20121101
Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein.	Progress in neuro-psychopharmacology & biological psychiatry 20121001
Rabbit syndrome following discontinuation of paliperidone in a patient with schizoaffective disorder.	Journal of clinical psychopharmacology 20121001
An analysis of potentially prolactin-related adverse events and abnormal prolactin values in randomized clinical trials with paliperidone palmitate.	The Annals of pharmacotherapy 20121001
Solid phase microextraction and LC-MS/MS for the determination of paliperidone after stereoselective fungal biotransformation of risperidone.	Analytica chimica acta 20120912
Paliperidone for irritability in adolescents and young adults with autistic disorder.	Psychopharmacology 20120901
Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial.	International clinical psychopharmacology 20120901
Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.	CNS drugs 20120901
Second-generation long-acting injectable antipsychotic agents: an overview.	Drug and therapeutics bulletin 20120901
The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia.	Progress in neuro-psychopharmacology & biological psychiatry 20120807
Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1.	Journal of pharmacokinetics and pharmacodynamics 20120801
Flexible dosing with paliperidone ER in the treatment of patients with acutely exacerbated schizophrenia: results from a single-arm, open-label study.	Current medical research and opinion 20120801
Paliperidone: a review of clinical trial data and clinical implications.	Clinical drug investigation 20120801
A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.	The Journal of clinical psychiatry 20120801
Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats.	Pharmaceutical research 20120701
Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability.	Expert opinion on drug metabolism & toxicology 20120701
Paliperidone palmitate for schizophrenia.	The Cochrane database of systematic reviews 20120613
Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia.	Schizophrenia research 20120601
Different impacts of aquaporin 4 and MAOA allele variation among olanzapine, risperidone, and paliperidone in schizophrenia.	Journal of clinical psychopharmacology 20120601
Risperidone and total 9-hydroxyrisperidone in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 2002-2010.	Therapeutic drug monitoring 20120601
Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia.	Drugs 20120528
Design of a long-term antipsychotic in situ forming implant and its release control method and mechanism.	International journal of pharmaceutics 20120510
Combination of citalopram plus paliperidone is better than citalopram alone in the treatment of somatoform disorder: results of a 6-week randomized study.	International clinical psychopharmacology 20120501
A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode.	Journal of affective disorders 20120501
Long-acting injectable antipsychotics for the maintenance treatment of bipolar disorder.	CNS drugs 20120501
Different safety profiles of risperidone and paliperidone extended-release: a double-blind, placebo-controlled trial with healthy volunteers.	Human psychopharmacology 20120501
Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers.	Journal of clinical pharmacy and therapeutics 20120401
Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone.	The Journal of pharmacology and experimental therapeutics 20120401
Practical guidelines on the use of paliperidone palmitate in schizophrenia.	Current medical research and opinion 20120401
Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study.	Therapeutic drug monitoring 20120401
Catatonia and encephalopathy associated with paliperidone palmitate.	Journal of clinical psychopharmacology 20120401
A stability-indicating ultra-performance liquid chromatographic method for estimation of related substances and degradants in paliperidone active pharmaceutical ingredient and its pharmaceutical dosage forms.	Journal of chromatographic science 20120401
Prolongation of cardiac ventricular repolarization under paliperidone: how and how much?	Journal of cardiovascular pharmacology 20120301
Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database.	PLoS medicine 20120301
Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia.	Reviews on recent clinical trials 20120201
Acute renal failure after paliperidone overdose: a case report.	Journal of clinical psychopharmacology 20120201
A change from risperidone long acting injection to paliperidone palmitate in an elderly patient--a cautionary tale.	The Australian and New Zealand journal of psychiatry 20120201
Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells.	Progress in neuro-psychopharmacology & biological psychiatry 20120110
Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose-response study.	Journal of affective disorders 20120101
QT prolongation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite paliperidone.	Human psychopharmacology 20120101
Oral-paliperidone-induced tardive dyskinesia: a case report.	General hospital psychiatry 20120101
Anaphylactoid reaction to paliperidone palmitate extended-release injectable suspension in a patient tolerant of oral risperidone.	American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120101
Effects of paliperidone extended release on the symptoms and functioning of schizophrenia.	BMC clinical pharmacology 20120101
The threshold rate of oral atypical anti-psychotic adherence at which paliperidone palmitate is cost saving.	Journal of medical economics 20120101
[Efficacy, tolerability and safety of paliperidone extended-release in the treatment of schizophrenia and schizoaffective disorder].	Rivista di psichiatria 20120101
In situ nondestructive sediment characterization and resuspendability evaluation of concentrated aqueous paliperidone palmitate suspensions in prefilled syringes by low-field one-dimensional pulsed-field gradient NMR profilometry.	Pharmaceutical development and technology 20120101
A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia.	BMC psychiatry 20120101
Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden.	Journal of medical economics 20120101
Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study.	Health and quality of life outcomes 20120101
Genetic polymorphisms in CYP2E1: association with schizophrenia susceptibility and risperidone response in the Chinese Han population.	PloS one 20120101
Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons.	International journal of general medicine 20120101
[Possibilities of the treatment of exacerbations of schizophrenia with the long acting atypical antipsychotic paliperidone palmitate].	Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20120101
Effect of the cytochrome P450 2D6*10 allele on risperidone metabolism in Japanese psychiatric patients.	Human psychopharmacology 20120101
Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece.	Annals of general psychiatry 20120101
Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults.	Patient preference and adherence 20120101
Management of antipsychotic treatment discontinuation and interruptions using model-based simulations.	Clinical pharmacology : advances and applications 20120101
Treatment with paliperidone in children with behavior disorders previously treated with risperidone: an open-label trial.	Clinical neuropharmacology 20120101
Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia.	Neuropsychiatric disease and treatment 20120101
Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents.	Innovations in clinical neuroscience 20120101
Aripiprazole reverses paliperidone-induced hyperprolactinemia.	Actas espanolas de psiquiatria 20120101
A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents.	Biological psychiatry 20111215
Social interaction and drug attitude effectiveness in patients with schizophrenia.	The Psychiatric quarterly 20111201
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	PLoS computational biology 20111201
Neuroprotection of paliperidone on SH-SY5Y cells against β-amyloid peptide(25-35), N-methyl-4-phenylpyridinium ion, and hydrogen peroxide-induced cell death.	Psychopharmacology 20111001
Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone.	Schizophrenia research 20111001
Comparing the influence of dopamine D₂ polymorphisms and plasma drug concentrations on the clinical response to risperidone.	Journal of clinical psychopharmacology 20111001
Enantioselective fungal biotransformation of risperidone in liquid culture medium by capillary electrophoresis and hollow fiber liquid-phase microextraction.	Electrophoresis 20111001
Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data.	CNS drugs 20111001
Paliperidone palmitate in a child with autistic disorder.	Journal of child and adolescent psychopharmacology 20111001
Effects of risperidone and paliperidone pre-treatment on locomotor response following prenatal immune activation.	Journal of psychiatric research 20110901
Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D610/10.	British journal of pharmacology 20110901
Effect of paliperidone and risperidone on extracellular glutamate in the prefrontal cortex of rats exposed to prenatal immune activation or MK-801.	Neuroscience letters 20110818
The interaction of antipsychotic drugs with lipids and subsequent lipid reorganization investigated using biophysical methods.	Biochimica et biophysica acta 20110801
Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE).	Current medical research and opinion 20110801
Osmotic-controlled release oral delivery system (OROS) paliperidone-related pruritic rash.	Journal of clinical psychopharmacology 20110801
A Post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia.	Innovations in clinical neuroscience 20110801
Paliperidone overdose with delayed onset of toxicity.	Annals of emergency medicine 20110701
Species independence in brain tissue binding using brain homogenates.	Drug metabolism and disposition: the biological fate of chemicals 20110701
MultiSimplex optimization of chromatographic separation and dansyl derivatization conditions in the ultra performance liquid chromatography-tandem mass spectrometry analysis of risperidone, 9-hydroxyrisperidone, monoamine and amino acid neurotransmitters in human urine.	Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110701
A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.	Progress in neuro-psychopharmacology & biological psychiatry 20110601
Prolongation of cardiac ventricular repolarization under paliperidone: how and how much?	Journal of cardiovascular pharmacology 20110601
Risperidone in schizophrenia: is there a role for therapeutic drug monitoring?	Therapeutic drug monitoring 20110601
Differential effects of antipsychotic medications on polyunsaturated fatty acid biosynthesis in rats: Relationship with liver delta6-desaturase expression.	Schizophrenia research 20110601
Paliperidone-related rabbit syndrome.	Journal of clinical psychopharmacology 20110601
Use of paliperidone in elderly patients with schizophrenia and schizoaffective disorder: a prospective open-label short-term pilot study.	Journal of clinical psychopharmacology 20110601
Oral paliperidone: a review of its use in the management of schizoaffective disorder.	CNS drugs 20110601
[Pharmacological properties of paliperidone ER (INVEGA(®)) and results of its clinical studies].	Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20110601
A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.	Journal of psychopharmacology (Oxford, England) 20110501
Lithium, but not fluoxetine or the corticotropin-releasing factor receptor 1 receptor antagonist R121919, increases cell proliferation in the adult dentate gyrus.	The Journal of pharmacology and experimental therapeutics 20110401
Paliperidone augmentation for treatment-resistant depression: a case report.	Journal of clinical psychopharmacology 20110401
Paliperidone-associated seizure after discontinuation of sodium valproate: a case report.	Journal of clinical psychopharmacology 20110401
Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents.	Journal of child and adolescent psychopharmacology 20110401
Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.	The Journal of clinical psychiatry 20110401
Paliperidone-associated atypical neuroleptic malignant syndrome: a case report.	Progress in neuro-psychopharmacology & biological psychiatry 20110330
Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study.	Journal of affective disorders 20110301
Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases.	Current drug safety 20110201
Change in employment status over 52 weeks in patients with schizophrenia: an observational study.	Current medical research and opinion 20110201
Paliperidone-induced leukopenia and neutropenia: a case report.	Progress in neuro-psychopharmacology & biological psychiatry 20110115
A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia.	Progress in neuro-psychopharmacology & biological psychiatry 20110115
Analysis of risperidone and 9-hydroxyrisperidone in human plasma, urine and saliva by MEPS-LC-UV.	Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110115
Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double-blind, placebo-controlled study.	International clinical psychopharmacology 20110101
Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis.	BMC psychiatry 20110101
Paliperidone-induced neuroleptic malignant syndrome.	The Journal of neuropsychiatry and clinical neurosciences 20110101
Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia.	BMC psychiatry 20110101
Cardiac safety of the electroconvulsive therapy-paliperidone combination: a preliminary study.	General hospital psychiatry 20110101
Paliperidone extended-release: does it have a place in antipsychotic therapy?	Drug design, development and therapy 20110101
Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial.	Annals of general psychiatry 20110101
The use of videoconferencing with patients with psychosis: a review of the literature.	Annals of general psychiatry 20110101
Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia.	Neuropsychiatric disease and treatment 20110101
Acute dystonia associated with paliperidone overdose.	Psychosomatics 20110101
Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial.	BMC psychiatry 20110101
Paliperidone-induced obsessive symptoms.	The Journal of neuropsychiatry and clinical neurosciences 20110101
Dose pattern and effectiveness of paliperidone extended-release tablets in patients with schizophrenia.	Clinical neuropharmacology 20110101
An in vitro evaluation of guanfacine as a substrate for P-glycoprotein.	Neuropsychiatric disease and treatment 20110101
The cost associated with administering risperidone long-acting injections in the Australian community.	BMC health services research 20110101
Improvement of oral dyskinesia after switching from aripiprazole to paliperidone: a case report.	The Journal of neuropsychiatry and clinical neurosciences 20110101
Manic symptoms during a switch from risperidone to paliperidone: a case report.	The Journal of neuropsychiatry and clinical neurosciences 20110101
Clinical utility of the risperidone formulations in the management of schizophrenia.	Neuropsychiatric disease and treatment 20110101
[Case of schizophrenia in which depressive and negative symptoms relapsed on switching from oral risperidone to risperidone long-acting injection].	Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica 20110101
Emergence of neuroleptic malignant syndrome while switching between risperidone and paliperidone.	The Journal of neuropsychiatry and clinical neurosciences 20110101
Tardive Tourette-like syndrome in a patient treated with paliperidone.	The Journal of neuropsychiatry and clinical neurosciences 20110101
Clozapine and other competitive antagonists reactivate risperidone-inactivated h5-HT7 receptors: radioligand binding and functional evidence for GPCR homodimer protomer interactions.	Psychopharmacology 20101201
Effect of cyamemazine on the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: a preliminary retrospective study.	Therapeutic drug monitoring 20101201
Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial.	Journal of clinical psychopharmacology 20101201
The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone.	European journal of clinical pharmacology 20101101
Tolerability of paliperidone: a meta-analysis of randomized, controlled trials.	International clinical psychopharmacology 20101101
Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.	The Journal of clinical psychiatry 20101101
Relative bioavailability of two oral formulations of risperidone 2 mg: A single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Brazilian volunteers.	Clinical therapeutics 20101101
A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia.	European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20101009
Paliperidone-induced mania-like symptoms: a case report.	Progress in neuro-psychopharmacology & biological psychiatry 20101001
Gender differences in the relationship between the risperidone metabolism and the plasma prolactin levels in psychiatric patients.	Progress in neuro-psychopharmacology & biological psychiatry 20101001
Differential effects of antipsychotic and antidepressant drugs on neurogenic regions in rats.	Brain research 20101001
Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers.	Journal of clinical psychopharmacology 20101001
Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania.	Expert opinion on pharmacotherapy 20101001
Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study.	International clinical psychopharmacology 20100901
A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia.	Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20100901
New antipsychotic drugs: how do their receptor-binding profiles compare?	The Journal of clinical psychiatry 20100901
[9-hydroxy-risperidone (9OHRIS) prevents stress-induced β-actin overexpression in rat hippocampus].	Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20100901
Relative bioavailability and pharmacokinetic comparison of two 2-mg risperidone tablet formulations: A single dose, randomized-sequence, double-blind, 2-way crossover study in healthy male volunteers in Thailand.	Clinical therapeutics 20100901
Using aripiprazole to attenuate paliperidone-induced hyperprolactinemia.	Progress in neuro-psychopharmacology & biological psychiatry 20100816
[Efficacy of paliperidone extended-release tablets in the improvement of social functions in schizophrenics: a randomized and controlled study].	Zhonghua yi xue za zhi 20100803
Serum concentrations of paliperidone versus risperidone and clinical effects.	European journal of clinical pharmacology 20100801
Neuroleptic malignant syndrome secondary to aripiprazole initiation in a clozapine-intolerant patient.	American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20100801
Studies on the acute toxicity, pharmacokinetics and pharmacodynamics of paliperidone derivatives--comparison to paliperidone and risperidone in mice and rats.	Basic & clinical pharmacology & toxicology 20100801
One-year open-label safety and efficacy study of paliperidone extended-release tablets in patients with schizophrenia.	CNS spectrums 20100801
Paliperidone extended release: a review of its use in the management of schizophrenia.	Drugs 20100709
Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients.	Journal of psychopharmacology (Oxford, England) 20100701
Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients.	Journal of psychopharmacology (Oxford, England) 20100701
A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia.	Journal of psychopharmacology (Oxford, England) 20100701
Long-acting injectable risperidone and metabolic ratio: a possible index of clinical outcome in treatment-resistant schizophrenic patients.	Psychopharmacology 20100701
Single-dose pharmacokinetics of paliperidone extended-release tablets in healthy Chinese subjects.	Human psychopharmacology 20100701
Paliperidone palmitate injection: Its efficacy, safety and tolerability in schizophrenia.	Drugs of today (Barcelona, Spain : 1998) 20100701
Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study.	The international journal of neuropsychopharmacology 20100601
Inconsistency in risperidone long-acting injection steady-state plasma levels when switching from deltoid to gluteal administration.	Journal of clinical pharmacology 20100601
Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety.	Journal of clinical pharmacology 20100601
Personal and social functioning in schizophrenia: defining a clinically meaningful measure of maintenance in relapse prevention.	Current medical research and opinion 20100601
Hyperprolactinaemia during treatment with paliperidone.	Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists 20100601
A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia.	Journal of clinical psychopharmacology 20100601
Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia.	International journal of clinical pharmacology and therapeutics 20100601
Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone.	International clinical psychopharmacology 20100501
A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder.	The Journal of clinical psychiatry 20100501
A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder.	Bipolar disorders 20100501
Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews.	Sao Paulo medical journal = Revista paulista de medicina 20100501
Paliperidone use in the elderly.	Current drug safety 20100401
Manic symptoms induced by paliperidone.	Journal of clinical psychopharmacology 20100401
Paliperidone overdose in a patient with schizophrenia.	Progress in neuro-psychopharmacology & biological psychiatry 20100317
Effects of quetiapine, risperidone, 9-hydroxyrisperidone and ziprasidone on the survival of human neuronal and immune cells in vitro.	Journal of psychopharmacology (Oxford, England) 20100301
A comparison of continuous subcutaneous paliperidone infusion and repeated subcutaneous injection of risperidone free-base in rats.	European psychiatry : the journal of the Association of European Psychiatrists 20100301
Modeling the effectiveness of paliperidone ER and olanzapine in schizophrenia: meta-analysis of 3 randomized, controlled clinical trials.	Journal of clinical pharmacology 20100301
Intramuscular paliperidone palmitate.	CNS drugs 20100301
Remission of drug-induced hepatitis after switching from risperidone to paliperidone.	The American journal of psychiatry 20100301
Serum concentrations, therapeutic response and side effects in children and adolescents with impulsive-aggressive symptoms during risperidone therapy.	Pharmacopsychiatry 20100301
Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.	Schizophrenia research 20100201
Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia.	Current medical research and opinion 20100201
Possible neuroleptic malignant syndrome during paliperidone administration: a case report.	Journal of clinical psychopharmacology 20100201
Paliperidone for irritability in autistic disorder.	Journal of child and adolescent psychopharmacology 20100201
Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia.	Early intervention in psychiatry 20100201
Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.	Clinical therapeutics 20100201
Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms.	Journal of affective disorders 20100101
Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication.	International journal of clinical practice 20100101
The pharmacokinetics of paliperidone versus risperidone.	Psychosomatics 20100101
Long-acting injectable antipsychotics: focus on olanzapine pamoate.	Neuropsychiatric disease and treatment 20100101
Once-monthly paliperidone injection for the treatment of schizophrenia.	Neuropsychiatric disease and treatment 20100101
Exploratory analysis of psychiatric-related utilization and costs associated with paliperidone ER compared with other oral atypical antipsychotics using pharmacy claims from an administrative database.	Journal of medical economics 20100101
Role of paliperidone extended-release in treatment of schizoaffective disorder.	Neuropsychiatric disease and treatment 20100101
Paliperidone-induced dystonic Dysphagia.	The Journal of neuropsychiatry and clinical neurosciences 20100101
[Non-fatal paliperidone overdose: a case report].	Turk psikiyatri dergisi = Turkish journal of psychiatry 20100101
Simultaneous determination of risperidone and 9-hydroxyrisperidone enantiomers in human blood plasma by liquid chromatography with electrochemical detection.	Journal of pharmaceutical and biomedical analysis 20091205
Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone.	Journal of clinical psychopharmacology 20091201
[Successful quetiapine therapy in psychotic patients with mood elevation].	Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20091201
In brief: Injectable paliperidone palmitate for schizophrenia.	The Medical letter on drugs and therapeutics 20091102
Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release.	Journal of clinical pharmacology 20091101
Second-generation antipsychotic long-acting injections: systematic review.	The British journal of psychiatry. Supplement 20091101
Effects of the antipsychotic risperidone on dopamine synthesis in human brain measured by positron emission tomography with L-[beta-11C]DOPA: a stabilizing effect for dopaminergic neurotransmission?	The Journal of neuroscience : the official journal of the Society for Neuroscience 20091028
Paliperidone for treatment of obsessive compulsive resistant symptoms in schizophrenia: a case report.	Progress in neuro-psychopharmacology & biological psychiatry 20091001
No pharmacokinetic interaction between paliperidone extended-release tablets and trimethoprim in healthy subjects.	Human psychopharmacology 20091001
Independent effect of paliperidone extended release on social functioning beyond its effect on positive and negative symptoms of schizophrenia: a mediation analysis.	Journal of clinical psychopharmacology 20091001
The influence of hepatic impairment on the pharmacokinetics of paliperidone.	International journal of clinical pharmacology and therapeutics 20091001
Determination of risperidone and 9-Hydroxyrisperidone using HPLC, in plasma of children and adolescents with emotional and behavioural disorders.	Biomedical chromatography : BMC 20090901
Human 5-HT7 receptor-induced inactivation of forskolin-stimulated adenylate cyclase by risperidone, 9-OH-risperidone and other 'inactivating antagonists'.	Molecular pharmacology 20090901
Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia.	Progress in neuro-psychopharmacology & biological psychiatry 20090831
Time resolved analysis of risperidone and 9-hydroxy-risperidone in hair using LC/MS-MS.	Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090815
Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone long-acting injection in Chinese patients with schizophrenic and schizoaffective disorders.	Psychiatry and clinical neurosciences 20090801
Serum levels of risperidone and its metabolite, 9-hydroxyrisperidone: correlation between drug concentration and clinical response.	Therapeutic drug monitoring 20090801
Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms.	Schizophrenia research 20090801
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.	Journal of medicinal chemistry 20090723
Impact of psychotic relapse definitions in assessing drug efficacy and costs: comparison of quetiapine XR, olanzapine and paliperidone ER.	Current medical research and opinion 20090701
The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets.	Pharmacopsychiatry 20090701
Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.	Human psychopharmacology 20090601
Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.	The American journal of psychiatry 20090601
Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients.	Journal of clinical psychopharmacology 20090601
In thrombin stimulated human platelets Citalopram, Promethazine, Risperidone, and Ziprasidone, but not Diazepam, may exert their pharmacological effects also through intercalation in membrane phospholipids in a receptor-independent manner.	Journal of chemical biology 20090601
Paliperidone suppresses the development of the aggressive phenotype in a developmentally sensitive animal model of escalated aggression.	Psychopharmacology 20090501
Secondary delusional parasitosis treated with paliperidone.	Clinical and experimental dermatology 20090401
An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment.	Clinical pharmacology and therapeutics 20090401
Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms.	The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20090301
Paliperidone in an adult patient with Asperger syndrome: case report.	Pharmacopsychiatry 20090301
Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release.	Expert opinion on drug delivery 20090301
Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists.	Molecular pharmacology 20090201
Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia.	Current medical research and opinion 20090201
Bioequivalence evaluation of two strengths of risperidone tablet formulations in healthy volunteers.	International journal of clinical pharmacology and therapeutics 20090201
[Psychiatry].	Revue medicale suisse 20090114
Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic.	Clinical pharmacokinetics 20090101
Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia.	Clinical interventions in aging 20090101
Paliperidon mediated modification of cortical inhibition.	Neuro endocrinology letters 20090101
Antipsychotic induced catatonia: a case of probable dementia with Lewy bodies.	The Journal of neuropsychiatry and clinical neurosciences 20090101
Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection.	Patient preference and adherence 20090101
[Treatment with paliperidone extended-release tablets in a case of resistant undifferentiated schizophrenia: clinical improvement with 12 mg and evaluation through 3TRE scale].	Rivista di psichiatria 20090101
Study of the complexation of risperidone and 9-hydroxyrisperidone with cyclodextrin hosts using affinity capillary electrophoresis and (1)H NMR spectroscopy.	Journal of chromatography. A 20081226
The disparity of pharmacokinetics and prolactin study for risperidone long-acting injection.	Journal of clinical psychopharmacology 20081201
What are the nursing implications when using paliperidone prolonged release for people with schizophrenia.	Journal of psychiatric and mental health nursing 20081201
Apparent seizure and atrial fibrillation associated with paliperidone.	American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20081115
Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study.	British journal of clinical pharmacology 20081101
Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies.	International clinical psychopharmacology 20081101
Paliperidone as a mood stabilizer: a pre-frontal cortex synaptoneurosomal proteomics comparison with lithium and valproic acid after chronic treatment reveals similarities in protein expression.	Brain research 20081003
ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety.	Therapeutic drug monitoring 20081001
Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy.	Therapeutic drug monitoring 20081001
Paliperidone extended-release for the treatment of schizophrenia.	Pharmacotherapy 20081001
Antipsychotic drugs inhibit the function of breast cancer resistance protein.	Basic & clinical pharmacology & toxicology 20081001
Gateways to clinical trials.	Methods and findings in experimental and clinical pharmacology 20081001
Risperidone long-acting injection: a review of its long term safety and efficacy.	Neuropsychiatric disease and treatment 20081001
Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia.	Neuropsychiatric disease and treatment 20081001
Choreatic symptoms during and after treatment with paliperidone and escitalopram.	Pharmacopsychiatry 20080901
[Paliperidone--a novel second-generation antipsychotic].	Ugeskrift for laeger 20080825
Toward prediction of alkane/water partition coefficients.	Journal of medicinal chemistry 20080710
Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone.	International clinical psychopharmacology 20080701
Validated LC-MS/MS methods for the determination of risperidone and the enantiomers of 9-hydroxyrisperidone in human plasma and urine.	Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080701
Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions.	Current drug metabolism 20080601
Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials.	Current medical research and opinion 20080601
Paliperidone for treatment of schizophrenia.	Schizophrenia bulletin 20080501
Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.	The Journal of clinical psychiatry 20080501
Paliperidone for schizophrenia.	The Cochrane database of systematic reviews 20080416
Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice.	Behavioural brain research 20080409
Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia.	Psychopharmacology 20080401
Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans.	Drug metabolism and disposition: the biological fate of chemicals 20080401
New drug update: 2007.	The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20080401
Paliperidone: An improvement over risperidone?	American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080301
Paliperidone for schizophrenia.	American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080301
Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder.	Psychoneuroendocrinology 20080201
Paliperidone-ER: first atypical antipsychotic with oral extended release formulation.	Expert review of neurotherapeutics 20080201
Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.	Clinical therapeutics 20080201
Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone.	Journal of clinical pharmacology 20080101
Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.	The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20080101
Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study.	Clinical drug investigation 20080101
Gateways to clinical trials. July-August 2008.	Methods and findings in experimental and clinical pharmacology 20080101
Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.	Drugs 20080101
Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.	Biological psychiatry 20071215
Paliperidone ER: a review of the clinical trial data.	Neuropsychiatric disease and treatment 20071201
Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.	Journal of psychopharmacology (Oxford, England) 20071101
The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia.	Expert opinion on drug safety 20071101
Sensitive liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat brain tissue.	Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20071015
Paliperidone: a new extended-release oral atypical antipsychotic.	Expert opinion on pharmacotherapy 20071001
Analytical and semipreparative enantioseparation of 9-hydroxyrisperidone, the main metabolite of risperidone, using high-performance liquid chromatography and capillary electrophoresis. Validation and determination of enantiomeric purity.	Journal of chromatography. A 20070907
Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons.	Psychopharmacology 20070901
A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia.	International clinical psychopharmacology 20070901
Enantioselective analysis of the antipsychotic 9-hydroxyrisperidone, main metabolite of risperidone, by chiral capillary EKC using dual CDs.	Electrophoresis 20070801
Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.	Schizophrenia research 20070701
Limitations in discerning the effects of risperidone and its 9-hydroxy metabolite on prolactin levels in a small study of patients with schizophrenia.	Human psychopharmacology 20070701
Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders.	Clinical therapeutics 20070701
Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients.	Progress in neuro-psychopharmacology & biological psychiatry 20070630
Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS/MS.	Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070601
Pharmacokinetics study for hyperprolactinemia among schizophrenics switched from risperidone to risperidone long-acting injection.	Journal of clinical psychopharmacology 20070601
[Development and identifiability analysis of parent-metabolite pharmacokinetic model for risperidone and its main active metabolite 9-hydroxyrisperidone].	Yao xue xue bao = Acta pharmaceutica Sinica 20070601
Molecule of the month. Paliperidone.	Drug news & perspectives 20070601
Paliperidone extended-release tablets: a new atypical antipsychotic.	Journal of psychosocial nursing and mental health services 20070501
A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.	Pharmacopsychiatry 20070501
Lack of bioequivalence between generic risperidone oral solution and originator risperidone tablets.	International journal of clinical pharmacology and therapeutics 20070501
Risperidone and paliperidone inhibit p-glycoprotein activity in vitro.	Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20070401
Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder.	Journal of pharmacokinetics and pharmacodynamics 20070401
Paliperidone: quo vadis?	International journal of clinical practice 20070401
Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic.	Drugs of today (Barcelona, Spain : 1998) 20070401
Paliperidone (Invega) for schizophrenia.	The Medical letter on drugs and therapeutics 20070312
Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.	Schizophrenia research 20070201
Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.	Journal of clinical psychopharmacology 20070201
Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism.	Journal of clinical psychopharmacology 20070201
FDA approves new antipsychotic.	American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20070201
Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability.	Clinical therapeutics 20070201
Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval.	Annals of general psychiatry 20070101
Valproic acid improves psychotic agitation without influencing plasma risperidone levels in schizophrenic patients.	Pharmacopsychiatry 20070101
Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders.	Clinical neuropharmacology 20070101
Paliperidone extended release.	CNS drugs 20070101
New drugs: paliperidone, dasatinib, and decitabine.	Journal of the American Pharmacists Association : JAPhA 20070101
New drug for schizophrenia.	FDA consumer 20070101
Possible neuroleptic malignant syndrome associated with paliperidone.	The Journal of neuropsychiatry and clinical neurosciences 20070101
Forty years of antipsychotic Drug research--from haloperidol to paliperidone--with Dr. Paul Janssen.	Arzneimittel-Forschung 20070101
Paliperidone: the evidence of its therapeutic value in schizophrenia.	Core evidence 20070101
Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite.	Human psychopharmacology 20061201
Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder.	Therapeutic drug monitoring 20061001
Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients.	Pharmacogenomics 20061001
Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein.	Psychopharmacology 20060901
Membrane transporter proteins: a challenge for CNS drug development.	Dialogues in clinical neuroscience 20060901
[Paliperidone].	Medizinische Monatsschrift fur Pharmazeuten 20060801
Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication.	Acta psychiatrica Scandinavica 20060701
Positive modulation of glutamatergic receptors potentiates the suppressive effects of antipsychotics on conditioned avoidance responding in rats.	Pharmacology, biochemistry, and behavior 20060601
Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes.	Archives of pharmacal research 20060601
[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations].	No to shinkei = Brain and nerve 20060601
Risperidone in the treatment of bipolar mania.	Neuropsychiatric disease and treatment 20060601
Optimization of the separation of some psychotropic drugs and their respective metabolites by liquid chromatography.	Journal of pharmaceutical and biomedical analysis 20060503
Intestinal uptake and biodistribution of novel polymeric micelles after oral administration.	Journal of controlled release : official journal of the Controlled Release Society 20060310
Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia.	Acta pharmacologica Sinica 20060301
A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.	The American journal of psychiatry 20060301
Liquid chromatography/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma.	Rapid communications in mass spectrometry : RCM 20060101
Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients.	Journal of clinical psychopharmacology 20051201
Plasma risperidone levels and clinical response in patients with first-episode psychosis.	Journal of clinical psychopharmacology 20051201
Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.	Clinical pharmacology and therapeutics 20051101
P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments.	Human psychopharmacology 20051001
Subtherapeutic risperidone serum concentrations in an adolescent during hemodialysis: a pharmacological puzzle.	Therapeutic drug monitoring 20051001
Risperidone plasma levels, clinical response and side-effects.	European archives of psychiatry and clinical neuroscience 20050801
Influence of age and gender on risperidone plasma concentrations.	Journal of psychopharmacology (Oxford, England) 20050701
Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition.	Clinical pharmacology and therapeutics 20050701
Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels.	The American journal of psychiatry 20050501
Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia.	The international journal of neuropsychopharmacology 20050301
Risperidone and breast-feeding.	Journal of psychopharmacology (Oxford, England) 20050301
Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.	International clinical psychopharmacology 20050301
Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service.	Therapeutic drug monitoring 20050201
The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model.	Drug metabolism and disposition: the biological fate of chemicals 20050101
Pharmacokinetic profile of long-acting injectable risperidone at steady-state: comparison with oral administration.	L'Encephale 20050101
The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein.	The international journal of neuropsychopharmacology 20041201
Identification and characterization of major degradation products of risperidone in bulk drug and pharmaceutical dosage forms.	Journal of pharmaceutical and biomedical analysis 20040921
A high-performance liquid chromatographic-atmospheric pressure chemical ionization-tandem mass spectrometric method for determination of risperidone and 9-hydroxyrisperidone in human plasma.	Journal of analytical toxicology 20040901
Plasma risperidone concentrations during combined treatment with sertraline.	Therapeutic drug monitoring 20040801
In vitro effects of risperidone and 9-hydroxy-risperidone on human platelet function, plasma coagulation, and fibrinolysis.	Clinical therapeutics 20040801
QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations.	Journal of psychopharmacology (Oxford, England) 20040601
Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes.	British journal of clinical pharmacology 20040501
Correlation between scores on Continuous Performance Test and plasma concentration for schizophrenic patients on risperidone.	Psychiatry and clinical neurosciences 20040401
Quantification of risperidone and 9-hydroxyrisperidone in plasma and saliva from adult and pediatric patients by liquid chromatography-mass spectrometry.	Journal of chromatography. A 20040213
Transfer of risperidone and 9-hydroxyrisperidone into human milk.	The Annals of pharmacotherapy 20040201
Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications.	Journal of child and adolescent psychopharmacology 20040101
Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone.	Therapeutic drug monitoring 20031201
Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia.	Therapeutic drug monitoring 20030601
Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers.	Clinical therapeutics 20030601
Effects of risperidone on psychometric and cognitive functions in healthy elderly volunteers.	Psychopharmacology 20030201
Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.	Journal of clinical pharmacology 20030201
Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography-tandem mass spectrometry.	Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030115
Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions.	Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030105
Pharmacokinetic and safety assessments of galantamine and risperidone after the two drugs are administered alone and together.	Journal of clinical pharmacology 20021201
Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients.	Pharmacopsychiatry 20021101
A colloidal graphite-coated emitter for sheathless capillary electrophoresis/nanoelectrospray ionization mass spectrometry.	Analytical chemistry 20021015
Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy.	Synapse (New York, N.Y.) 20021001
Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in plasma after overdose.	Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020605
Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel.	The Journal of pharmacology and experimental therapeutics 20020501
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.	The Journal of biological chemistry 20020419
In vivo and in vitro myocardial binding of risperidone and 9-hydroxyrisperidone.	Toxicology and applied pharmacology 20020415
The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients.	Pharmacopsychiatry 20020301
Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats.	Psychopharmacology 20020201
Risperidone and 9-hydroxyrisperidone concentrations are not dependent on age or creatinine clearance among elderly subjects.	Journal of geriatric psychiatry and neurology 20020101
Sequential changes in the plasma concentration of risperidone following intentional overdose.	Clinical neuropharmacology 20020101
Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes.	Drug metabolism and disposition: the biological fate of chemicals 20011001
Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine.	Therapeutic drug monitoring 20010601
Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels.	European psychiatry : the journal of the Association of European Psychiatrists 20010201
Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.	Psychopharmacology 20010101
Effects of two atypical neuroleptics, olanzapine and risperidone, on the function of the urinary bladder and the external urethral sphincter in anesthetized rats.	BMC pharmacology 20010101
Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study.	Neuropsychobiology 20010101
Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.	Psychopharmacology 19991201
Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.	The Journal of clinical psychiatry 19940501

Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein.

Progress in neuro-psychopharmacology & biological psychiatry 20121001

Rabbit syndrome following discontinuation of paliperidone in a patient with schizoaffective disorder.

Journal of clinical psychopharmacology 20121001

An analysis of potentially prolactin-related adverse events and abnormal prolactin values in randomized clinical trials with paliperidone palmitate.

The Annals of pharmacotherapy 20121001

Solid phase microextraction and LC-MS/MS for the determination of paliperidone after stereoselective fungal biotransformation of risperidone.

Analytica chimica acta 20120912

Paliperidone for irritability in adolescents and young adults with autistic disorder.

Psychopharmacology 20120901

Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial.

International clinical psychopharmacology 20120901

Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.

CNS drugs 20120901

Second-generation long-acting injectable antipsychotic agents: an overview.

Drug and therapeutics bulletin 20120901

The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia.

Progress in neuro-psychopharmacology & biological psychiatry 20120807

Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1.

Journal of pharmacokinetics and pharmacodynamics 20120801

Flexible dosing with paliperidone ER in the treatment of patients with acutely exacerbated schizophrenia: results from a single-arm, open-label study.

Current medical research and opinion 20120801

Paliperidone: a review of clinical trial data and clinical implications.

Clinical drug investigation 20120801

A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.

The Journal of clinical psychiatry 20120801

Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats.

Pharmaceutical research 20120701

Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability.

Expert opinion on drug metabolism & toxicology 20120701

Paliperidone palmitate for schizophrenia.

The Cochrane database of systematic reviews 20120613

Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia.

Schizophrenia research 20120601

Different impacts of aquaporin 4 and MAOA allele variation among olanzapine, risperidone, and paliperidone in schizophrenia.

Journal of clinical psychopharmacology 20120601

Risperidone and total 9-hydroxyrisperidone in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 2002-2010.

Therapeutic drug monitoring 20120601

Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia.

Drugs 20120528

Design of a long-term antipsychotic in situ forming implant and its release control method and mechanism.

International journal of pharmaceutics 20120510

Combination of citalopram plus paliperidone is better than citalopram alone in the treatment of somatoform disorder: results of a 6-week randomized study.

International clinical psychopharmacology 20120501

A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode.

Journal of affective disorders 20120501

Long-acting injectable antipsychotics for the maintenance treatment of bipolar disorder.

CNS drugs 20120501

Different safety profiles of risperidone and paliperidone extended-release: a double-blind, placebo-controlled trial with healthy volunteers.

Human psychopharmacology 20120501

Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers.

Journal of clinical pharmacy and therapeutics 20120401

Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone.

The Journal of pharmacology and experimental therapeutics 20120401

Practical guidelines on the use of paliperidone palmitate in schizophrenia.

Current medical research and opinion 20120401

Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study.

Therapeutic drug monitoring 20120401

Catatonia and encephalopathy associated with paliperidone palmitate.

Journal of clinical psychopharmacology 20120401

A stability-indicating ultra-performance liquid chromatographic method for estimation of related substances and degradants in paliperidone active pharmaceutical ingredient and its pharmaceutical dosage forms.

Journal of chromatographic science 20120401

Prolongation of cardiac ventricular repolarization under paliperidone: how and how much?

Journal of cardiovascular pharmacology 20120301

Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database.

PLoS medicine 20120301

Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia.

Reviews on recent clinical trials 20120201

Acute renal failure after paliperidone overdose: a case report.

Journal of clinical psychopharmacology 20120201

A change from risperidone long acting injection to paliperidone palmitate in an elderly patient--a cautionary tale.

The Australian and New Zealand journal of psychiatry 20120201

Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells.

Progress in neuro-psychopharmacology & biological psychiatry 20120110

Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose-response study.

Journal of affective disorders 20120101

QT prolongation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite paliperidone.

Human psychopharmacology 20120101

Oral-paliperidone-induced tardive dyskinesia: a case report.

General hospital psychiatry 20120101

Anaphylactoid reaction to paliperidone palmitate extended-release injectable suspension in a patient tolerant of oral risperidone.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120101

Effects of paliperidone extended release on the symptoms and functioning of schizophrenia.

BMC clinical pharmacology 20120101

The threshold rate of oral atypical anti-psychotic adherence at which paliperidone palmitate is cost saving.

Journal of medical economics 20120101

[Efficacy, tolerability and safety of paliperidone extended-release in the treatment of schizophrenia and schizoaffective disorder].

Rivista di psichiatria 20120101

In situ nondestructive sediment characterization and resuspendability evaluation of concentrated aqueous paliperidone palmitate suspensions in prefilled syringes by low-field one-dimensional pulsed-field gradient NMR profilometry.

Pharmaceutical development and technology 20120101

A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia.

BMC psychiatry 20120101

Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden.

Journal of medical economics 20120101

Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study.

Health and quality of life outcomes 20120101

Genetic polymorphisms in CYP2E1: association with schizophrenia susceptibility and risperidone response in the Chinese Han population.

PloS one 20120101

Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons.

International journal of general medicine 20120101

[Possibilities of the treatment of exacerbations of schizophrenia with the long acting atypical antipsychotic paliperidone palmitate].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20120101

Effect of the cytochrome P450 2D6*10 allele on risperidone metabolism in Japanese psychiatric patients.

Human psychopharmacology 20120101

Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece.

Annals of general psychiatry 20120101

Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults.

Patient preference and adherence 20120101

Management of antipsychotic treatment discontinuation and interruptions using model-based simulations.

Clinical pharmacology : advances and applications 20120101

Treatment with paliperidone in children with behavior disorders previously treated with risperidone: an open-label trial.

Clinical neuropharmacology 20120101

Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia.

Neuropsychiatric disease and treatment 20120101

Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents.

Innovations in clinical neuroscience 20120101

Aripiprazole reverses paliperidone-induced hyperprolactinemia.

Actas espanolas de psiquiatria 20120101

A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents.

Biological psychiatry 20111215

Social interaction and drug attitude effectiveness in patients with schizophrenia.

The Psychiatric quarterly 20111201

Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

PLoS computational biology 20111201

Neuroprotection of paliperidone on SH-SY5Y cells against β-amyloid peptide(25-35), N-methyl-4-phenylpyridinium ion, and hydrogen peroxide-induced cell death.

Psychopharmacology 20111001

Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone.

Schizophrenia research 20111001

Comparing the influence of dopamine D₂ polymorphisms and plasma drug concentrations on the clinical response to risperidone.

Journal of clinical psychopharmacology 20111001

Enantioselective fungal biotransformation of risperidone in liquid culture medium by capillary electrophoresis and hollow fiber liquid-phase microextraction.

Electrophoresis 20111001

Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data.

CNS drugs 20111001

Paliperidone palmitate in a child with autistic disorder.

Journal of child and adolescent psychopharmacology 20111001

Effects of risperidone and paliperidone pre-treatment on locomotor response following prenatal immune activation.

Journal of psychiatric research 20110901

Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10/*10.

British journal of pharmacology 20110901

Effect of paliperidone and risperidone on extracellular glutamate in the prefrontal cortex of rats exposed to prenatal immune activation or MK-801.

Neuroscience letters 20110818

The interaction of antipsychotic drugs with lipids and subsequent lipid reorganization investigated using biophysical methods.

Biochimica et biophysica acta 20110801

Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE).

Current medical research and opinion 20110801

Osmotic-controlled release oral delivery system (OROS) paliperidone-related pruritic rash.

Journal of clinical psychopharmacology 20110801

A Post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia.

Innovations in clinical neuroscience 20110801

Paliperidone overdose with delayed onset of toxicity.

Annals of emergency medicine 20110701

Species independence in brain tissue binding using brain homogenates.

Drug metabolism and disposition: the biological fate of chemicals 20110701

MultiSimplex optimization of chromatographic separation and dansyl derivatization conditions in the ultra performance liquid chromatography-tandem mass spectrometry analysis of risperidone, 9-hydroxyrisperidone, monoamine and amino acid neurotransmitters in human urine.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110701

A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.

Progress in neuro-psychopharmacology & biological psychiatry 20110601

Prolongation of cardiac ventricular repolarization under paliperidone: how and how much?

Journal of cardiovascular pharmacology 20110601

Risperidone in schizophrenia: is there a role for therapeutic drug monitoring?

Therapeutic drug monitoring 20110601

Differential effects of antipsychotic medications on polyunsaturated fatty acid biosynthesis in rats: Relationship with liver delta6-desaturase expression.

Schizophrenia research 20110601

Paliperidone-related rabbit syndrome.

Journal of clinical psychopharmacology 20110601

Use of paliperidone in elderly patients with schizophrenia and schizoaffective disorder: a prospective open-label short-term pilot study.

Journal of clinical psychopharmacology 20110601

Oral paliperidone: a review of its use in the management of schizoaffective disorder.

CNS drugs 20110601

[Pharmacological properties of paliperidone ER (INVEGA(®)) and results of its clinical studies].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20110601

A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.

Journal of psychopharmacology (Oxford, England) 20110501

Lithium, but not fluoxetine or the corticotropin-releasing factor receptor 1 receptor antagonist R121919, increases cell proliferation in the adult dentate gyrus.

The Journal of pharmacology and experimental therapeutics 20110401

Paliperidone augmentation for treatment-resistant depression: a case report.

Journal of clinical psychopharmacology 20110401

Paliperidone-associated seizure after discontinuation of sodium valproate: a case report.

Journal of clinical psychopharmacology 20110401

Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents.

Journal of child and adolescent psychopharmacology 20110401

Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.

The Journal of clinical psychiatry 20110401

Paliperidone-associated atypical neuroleptic malignant syndrome: a case report.

Progress in neuro-psychopharmacology & biological psychiatry 20110330

Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study.

Journal of affective disorders 20110301

Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases.

Current drug safety 20110201

Change in employment status over 52 weeks in patients with schizophrenia: an observational study.

Current medical research and opinion 20110201

Paliperidone-induced leukopenia and neutropenia: a case report.

Progress in neuro-psychopharmacology & biological psychiatry 20110115

A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia.

Progress in neuro-psychopharmacology & biological psychiatry 20110115

Analysis of risperidone and 9-hydroxyrisperidone in human plasma, urine and saliva by MEPS-LC-UV.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110115

Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double-blind, placebo-controlled study.

International clinical psychopharmacology 20110101

Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis.

BMC psychiatry 20110101

Paliperidone-induced neuroleptic malignant syndrome.

The Journal of neuropsychiatry and clinical neurosciences 20110101

Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia.

BMC psychiatry 20110101

Cardiac safety of the electroconvulsive therapy-paliperidone combination: a preliminary study.

General hospital psychiatry 20110101

Paliperidone extended-release: does it have a place in antipsychotic therapy?

Drug design, development and therapy 20110101

Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial.

Annals of general psychiatry 20110101

The use of videoconferencing with patients with psychosis: a review of the literature.

Annals of general psychiatry 20110101

Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia.

Neuropsychiatric disease and treatment 20110101

Acute dystonia associated with paliperidone overdose.

Psychosomatics 20110101

Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial.

BMC psychiatry 20110101

Paliperidone-induced obsessive symptoms.

The Journal of neuropsychiatry and clinical neurosciences 20110101

Dose pattern and effectiveness of paliperidone extended-release tablets in patients with schizophrenia.

Clinical neuropharmacology 20110101

An in vitro evaluation of guanfacine as a substrate for P-glycoprotein.

Neuropsychiatric disease and treatment 20110101

The cost associated with administering risperidone long-acting injections in the Australian community.

BMC health services research 20110101

Improvement of oral dyskinesia after switching from aripiprazole to paliperidone: a case report.

The Journal of neuropsychiatry and clinical neurosciences 20110101

Manic symptoms during a switch from risperidone to paliperidone: a case report.

The Journal of neuropsychiatry and clinical neurosciences 20110101

Clinical utility of the risperidone formulations in the management of schizophrenia.

Neuropsychiatric disease and treatment 20110101

[Case of schizophrenia in which depressive and negative symptoms relapsed on switching from oral risperidone to risperidone long-acting injection].

Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica 20110101

Emergence of neuroleptic malignant syndrome while switching between risperidone and paliperidone.

The Journal of neuropsychiatry and clinical neurosciences 20110101

Tardive Tourette-like syndrome in a patient treated with paliperidone.

The Journal of neuropsychiatry and clinical neurosciences 20110101

Clozapine and other competitive antagonists reactivate risperidone-inactivated h5-HT7 receptors: radioligand binding and functional evidence for GPCR homodimer protomer interactions.

Psychopharmacology 20101201

Effect of cyamemazine on the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: a preliminary retrospective study.

Therapeutic drug monitoring 20101201

Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial.

Journal of clinical psychopharmacology 20101201

The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone.

European journal of clinical pharmacology 20101101

Tolerability of paliperidone: a meta-analysis of randomized, controlled trials.

International clinical psychopharmacology 20101101

Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.

The Journal of clinical psychiatry 20101101

Relative bioavailability of two oral formulations of risperidone 2 mg: A single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Brazilian volunteers.

Clinical therapeutics 20101101

A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20101009

Paliperidone-induced mania-like symptoms: a case report.

Progress in neuro-psychopharmacology & biological psychiatry 20101001

Gender differences in the relationship between the risperidone metabolism and the plasma prolactin levels in psychiatric patients.

Progress in neuro-psychopharmacology & biological psychiatry 20101001

Differential effects of antipsychotic and antidepressant drugs on neurogenic regions in rats.

Brain research 20101001

Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers.

Journal of clinical psychopharmacology 20101001

Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania.

Expert opinion on pharmacotherapy 20101001

Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study.

International clinical psychopharmacology 20100901

A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20100901

New antipsychotic drugs: how do their receptor-binding profiles compare?

The Journal of clinical psychiatry 20100901

[9-hydroxy-risperidone (9OHRIS) prevents stress-induced β-actin overexpression in rat hippocampus].

Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20100901

Relative bioavailability and pharmacokinetic comparison of two 2-mg risperidone tablet formulations: A single dose, randomized-sequence, double-blind, 2-way crossover study in healthy male volunteers in Thailand.

Clinical therapeutics 20100901

Using aripiprazole to attenuate paliperidone-induced hyperprolactinemia.

Progress in neuro-psychopharmacology & biological psychiatry 20100816

[Efficacy of paliperidone extended-release tablets in the improvement of social functions in schizophrenics: a randomized and controlled study].

Zhonghua yi xue za zhi 20100803

Serum concentrations of paliperidone versus risperidone and clinical effects.

European journal of clinical pharmacology 20100801

Neuroleptic malignant syndrome secondary to aripiprazole initiation in a clozapine-intolerant patient.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20100801

Studies on the acute toxicity, pharmacokinetics and pharmacodynamics of paliperidone derivatives--comparison to paliperidone and risperidone in mice and rats.

Basic & clinical pharmacology & toxicology 20100801

One-year open-label safety and efficacy study of paliperidone extended-release tablets in patients with schizophrenia.

CNS spectrums 20100801

Paliperidone extended release: a review of its use in the management of schizophrenia.

Drugs 20100709

Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients.

Journal of psychopharmacology (Oxford, England) 20100701

Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients.

Journal of psychopharmacology (Oxford, England) 20100701

A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia.

Journal of psychopharmacology (Oxford, England) 20100701

Long-acting injectable risperidone and metabolic ratio: a possible index of clinical outcome in treatment-resistant schizophrenic patients.

Psychopharmacology 20100701

Single-dose pharmacokinetics of paliperidone extended-release tablets in healthy Chinese subjects.

Human psychopharmacology 20100701

Paliperidone palmitate injection: Its efficacy, safety and tolerability in schizophrenia.

Drugs of today (Barcelona, Spain : 1998) 20100701

Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study.

The international journal of neuropsychopharmacology 20100601

Inconsistency in risperidone long-acting injection steady-state plasma levels when switching from deltoid to gluteal administration.

Journal of clinical pharmacology 20100601

Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety.

Journal of clinical pharmacology 20100601

Personal and social functioning in schizophrenia: defining a clinically meaningful measure of maintenance in relapse prevention.

Current medical research and opinion 20100601

Hyperprolactinaemia during treatment with paliperidone.

Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists 20100601

A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia.

Journal of clinical psychopharmacology 20100601

Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia.

International journal of clinical pharmacology and therapeutics 20100601

Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone.

International clinical psychopharmacology 20100501

A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder.

The Journal of clinical psychiatry 20100501

A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder.

Bipolar disorders 20100501

Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews.

Sao Paulo medical journal = Revista paulista de medicina 20100501

Paliperidone use in the elderly.

Current drug safety 20100401

Manic symptoms induced by paliperidone.

Journal of clinical psychopharmacology 20100401

Paliperidone overdose in a patient with schizophrenia.

Progress in neuro-psychopharmacology & biological psychiatry 20100317

Effects of quetiapine, risperidone, 9-hydroxyrisperidone and ziprasidone on the survival of human neuronal and immune cells in vitro.

Journal of psychopharmacology (Oxford, England) 20100301

A comparison of continuous subcutaneous paliperidone infusion and repeated subcutaneous injection of risperidone free-base in rats.

European psychiatry : the journal of the Association of European Psychiatrists 20100301

Modeling the effectiveness of paliperidone ER and olanzapine in schizophrenia: meta-analysis of 3 randomized, controlled clinical trials.

Journal of clinical pharmacology 20100301

Intramuscular paliperidone palmitate.

CNS drugs 20100301

Remission of drug-induced hepatitis after switching from risperidone to paliperidone.

The American journal of psychiatry 20100301

Serum concentrations, therapeutic response and side effects in children and adolescents with impulsive-aggressive symptoms during risperidone therapy.

Pharmacopsychiatry 20100301

Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.

Schizophrenia research 20100201

Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia.

Current medical research and opinion 20100201

Possible neuroleptic malignant syndrome during paliperidone administration: a case report.

Journal of clinical psychopharmacology 20100201

Paliperidone for irritability in autistic disorder.

Journal of child and adolescent psychopharmacology 20100201

Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia.

Early intervention in psychiatry 20100201

Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.

Clinical therapeutics 20100201

Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms.

Journal of affective disorders 20100101

Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication.

International journal of clinical practice 20100101

The pharmacokinetics of paliperidone versus risperidone.

Psychosomatics 20100101

Long-acting injectable antipsychotics: focus on olanzapine pamoate.

Neuropsychiatric disease and treatment 20100101

Once-monthly paliperidone injection for the treatment of schizophrenia.

Neuropsychiatric disease and treatment 20100101

Exploratory analysis of psychiatric-related utilization and costs associated with paliperidone ER compared with other oral atypical antipsychotics using pharmacy claims from an administrative database.

Journal of medical economics 20100101

Role of paliperidone extended-release in treatment of schizoaffective disorder.

Neuropsychiatric disease and treatment 20100101

Paliperidone-induced dystonic Dysphagia.

The Journal of neuropsychiatry and clinical neurosciences 20100101

[Non-fatal paliperidone overdose: a case report].

Turk psikiyatri dergisi = Turkish journal of psychiatry 20100101

Simultaneous determination of risperidone and 9-hydroxyrisperidone enantiomers in human blood plasma by liquid chromatography with electrochemical detection.

Journal of pharmaceutical and biomedical analysis 20091205

Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone.

Journal of clinical psychopharmacology 20091201

[Successful quetiapine therapy in psychotic patients with mood elevation].

Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20091201

In brief: Injectable paliperidone palmitate for schizophrenia.

The Medical letter on drugs and therapeutics 20091102

Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release.

Journal of clinical pharmacology 20091101

Second-generation antipsychotic long-acting injections: systematic review.

The British journal of psychiatry. Supplement 20091101

Effects of the antipsychotic risperidone on dopamine synthesis in human brain measured by positron emission tomography with L-[beta-11C]DOPA: a stabilizing effect for dopaminergic neurotransmission?

The Journal of neuroscience : the official journal of the Society for Neuroscience 20091028

Paliperidone for treatment of obsessive compulsive resistant symptoms in schizophrenia: a case report.

Progress in neuro-psychopharmacology & biological psychiatry 20091001

No pharmacokinetic interaction between paliperidone extended-release tablets and trimethoprim in healthy subjects.

Human psychopharmacology 20091001

Independent effect of paliperidone extended release on social functioning beyond its effect on positive and negative symptoms of schizophrenia: a mediation analysis.

Journal of clinical psychopharmacology 20091001

The influence of hepatic impairment on the pharmacokinetics of paliperidone.

International journal of clinical pharmacology and therapeutics 20091001

Determination of risperidone and 9-Hydroxyrisperidone using HPLC, in plasma of children and adolescents with emotional and behavioural disorders.

Biomedical chromatography : BMC 20090901

Human 5-HT7 receptor-induced inactivation of forskolin-stimulated adenylate cyclase by risperidone, 9-OH-risperidone and other 'inactivating antagonists'.

Molecular pharmacology 20090901

Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia.

Progress in neuro-psychopharmacology & biological psychiatry 20090831

Time resolved analysis of risperidone and 9-hydroxy-risperidone in hair using LC/MS-MS.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090815

Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone long-acting injection in Chinese patients with schizophrenic and schizoaffective disorders.

Psychiatry and clinical neurosciences 20090801

Serum levels of risperidone and its metabolite, 9-hydroxyrisperidone: correlation between drug concentration and clinical response.

Therapeutic drug monitoring 20090801

Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms.

Schizophrenia research 20090801

Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.

Journal of medicinal chemistry 20090723

Impact of psychotic relapse definitions in assessing drug efficacy and costs: comparison of quetiapine XR, olanzapine and paliperidone ER.

Current medical research and opinion 20090701

The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets.

Pharmacopsychiatry 20090701

Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.

Human psychopharmacology 20090601

Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.

The American journal of psychiatry 20090601

Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients.

Journal of clinical psychopharmacology 20090601

In thrombin stimulated human platelets Citalopram, Promethazine, Risperidone, and Ziprasidone, but not Diazepam, may exert their pharmacological effects also through intercalation in membrane phospholipids in a receptor-independent manner.

Journal of chemical biology 20090601

Paliperidone suppresses the development of the aggressive phenotype in a developmentally sensitive animal model of escalated aggression.

Psychopharmacology 20090501

Secondary delusional parasitosis treated with paliperidone.

Clinical and experimental dermatology 20090401

An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment.

Clinical pharmacology and therapeutics 20090401

Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms.

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20090301

Paliperidone in an adult patient with Asperger syndrome: case report.

Pharmacopsychiatry 20090301

Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release.

Expert opinion on drug delivery 20090301

Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists.

Molecular pharmacology 20090201

Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia.

Current medical research and opinion 20090201

Bioequivalence evaluation of two strengths of risperidone tablet formulations in healthy volunteers.

International journal of clinical pharmacology and therapeutics 20090201

[Psychiatry].

Revue medicale suisse 20090114

Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic.

Clinical pharmacokinetics 20090101

Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia.

Clinical interventions in aging 20090101

Paliperidon mediated modification of cortical inhibition.

Neuro endocrinology letters 20090101

Antipsychotic induced catatonia: a case of probable dementia with Lewy bodies.

The Journal of neuropsychiatry and clinical neurosciences 20090101

Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection.

Patient preference and adherence 20090101

[Treatment with paliperidone extended-release tablets in a case of resistant undifferentiated schizophrenia: clinical improvement with 12 mg and evaluation through 3TRE scale].

Rivista di psichiatria 20090101

Study of the complexation of risperidone and 9-hydroxyrisperidone with cyclodextrin hosts using affinity capillary electrophoresis and (1)H NMR spectroscopy.

Journal of chromatography. A 20081226

The disparity of pharmacokinetics and prolactin study for risperidone long-acting injection.

Journal of clinical psychopharmacology 20081201

What are the nursing implications when using paliperidone prolonged release for people with schizophrenia.

Journal of psychiatric and mental health nursing 20081201

Apparent seizure and atrial fibrillation associated with paliperidone.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20081115

Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study.

British journal of clinical pharmacology 20081101

Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies.

International clinical psychopharmacology 20081101

Paliperidone as a mood stabilizer: a pre-frontal cortex synaptoneurosomal proteomics comparison with lithium and valproic acid after chronic treatment reveals similarities in protein expression.

Brain research 20081003

ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety.

Therapeutic drug monitoring 20081001

Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy.

Therapeutic drug monitoring 20081001

Paliperidone extended-release for the treatment of schizophrenia.

Pharmacotherapy 20081001

Antipsychotic drugs inhibit the function of breast cancer resistance protein.

Basic & clinical pharmacology & toxicology 20081001

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20081001

Risperidone long-acting injection: a review of its long term safety and efficacy.

Neuropsychiatric disease and treatment 20081001

Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia.

Neuropsychiatric disease and treatment 20081001

Choreatic symptoms during and after treatment with paliperidone and escitalopram.

Pharmacopsychiatry 20080901

[Paliperidone--a novel second-generation antipsychotic].

Ugeskrift for laeger 20080825

Toward prediction of alkane/water partition coefficients.

Journal of medicinal chemistry 20080710

Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone.

International clinical psychopharmacology 20080701

Validated LC-MS/MS methods for the determination of risperidone and the enantiomers of 9-hydroxyrisperidone in human plasma and urine.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080701

Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions.

Current drug metabolism 20080601

Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials.

Current medical research and opinion 20080601

Paliperidone for treatment of schizophrenia.

Schizophrenia bulletin 20080501

Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.

The Journal of clinical psychiatry 20080501

Paliperidone for schizophrenia.

The Cochrane database of systematic reviews 20080416

Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice.

Behavioural brain research 20080409

Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia.

Psychopharmacology 20080401

Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans.

Drug metabolism and disposition: the biological fate of chemicals 20080401

New drug update: 2007.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20080401

Paliperidone: An improvement over risperidone?

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080301

Paliperidone for schizophrenia.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080301

Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder.

Psychoneuroendocrinology 20080201

Paliperidone-ER: first atypical antipsychotic with oral extended release formulation.

Expert review of neurotherapeutics 20080201

Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.

Clinical therapeutics 20080201

Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone.

Journal of clinical pharmacology 20080101

Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20080101

Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study.

Clinical drug investigation 20080101

Gateways to clinical trials. July-August 2008.

Methods and findings in experimental and clinical pharmacology 20080101

Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.

Drugs 20080101

Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.

Biological psychiatry 20071215

Paliperidone ER: a review of the clinical trial data.

Neuropsychiatric disease and treatment 20071201

Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.

Journal of psychopharmacology (Oxford, England) 20071101

The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia.

Expert opinion on drug safety 20071101

Sensitive liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat brain tissue.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20071015

Paliperidone: a new extended-release oral atypical antipsychotic.

Expert opinion on pharmacotherapy 20071001

Analytical and semipreparative enantioseparation of 9-hydroxyrisperidone, the main metabolite of risperidone, using high-performance liquid chromatography and capillary electrophoresis. Validation and determination of enantiomeric purity.

Journal of chromatography. A 20070907

Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons.

Psychopharmacology 20070901

A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia.

International clinical psychopharmacology 20070901

Enantioselective analysis of the antipsychotic 9-hydroxyrisperidone, main metabolite of risperidone, by chiral capillary EKC using dual CDs.

Electrophoresis 20070801

Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.

Schizophrenia research 20070701

Limitations in discerning the effects of risperidone and its 9-hydroxy metabolite on prolactin levels in a small study of patients with schizophrenia.

Human psychopharmacology 20070701

Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders.

Clinical therapeutics 20070701

Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients.

Progress in neuro-psychopharmacology & biological psychiatry 20070630

Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS/MS.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070601

Pharmacokinetics study for hyperprolactinemia among schizophrenics switched from risperidone to risperidone long-acting injection.

Journal of clinical psychopharmacology 20070601

[Development and identifiability analysis of parent-metabolite pharmacokinetic model for risperidone and its main active metabolite 9-hydroxyrisperidone].

Yao xue xue bao = Acta pharmaceutica Sinica 20070601

Molecule of the month. Paliperidone.

Drug news & perspectives 20070601

Paliperidone extended-release tablets: a new atypical antipsychotic.

Journal of psychosocial nursing and mental health services 20070501

A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.

Pharmacopsychiatry 20070501

Lack of bioequivalence between generic risperidone oral solution and originator risperidone tablets.

International journal of clinical pharmacology and therapeutics 20070501

Risperidone and paliperidone inhibit p-glycoprotein activity in vitro.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20070401

Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder.

Journal of pharmacokinetics and pharmacodynamics 20070401

Paliperidone: quo vadis?

International journal of clinical practice 20070401

Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic.

Drugs of today (Barcelona, Spain : 1998) 20070401

Paliperidone (Invega) for schizophrenia.

The Medical letter on drugs and therapeutics 20070312

Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.

Schizophrenia research 20070201

Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.

Journal of clinical psychopharmacology 20070201

Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism.

Journal of clinical psychopharmacology 20070201

FDA approves new antipsychotic.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20070201

Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability.

Clinical therapeutics 20070201

Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval.

Annals of general psychiatry 20070101

Valproic acid improves psychotic agitation without influencing plasma risperidone levels in schizophrenic patients.

Pharmacopsychiatry 20070101

Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders.

Clinical neuropharmacology 20070101

Paliperidone extended release.

CNS drugs 20070101

New drugs: paliperidone, dasatinib, and decitabine.

Journal of the American Pharmacists Association : JAPhA 20070101

New drug for schizophrenia.

FDA consumer 20070101

Possible neuroleptic malignant syndrome associated with paliperidone.

The Journal of neuropsychiatry and clinical neurosciences 20070101

Forty years of antipsychotic Drug research--from haloperidol to paliperidone--with Dr. Paul Janssen.

Arzneimittel-Forschung 20070101

Paliperidone: the evidence of its therapeutic value in schizophrenia.

Core evidence 20070101

Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite.

Human psychopharmacology 20061201

Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder.

Therapeutic drug monitoring 20061001

Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients.

Pharmacogenomics 20061001

Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein.

Psychopharmacology 20060901

Membrane transporter proteins: a challenge for CNS drug development.

Dialogues in clinical neuroscience 20060901

[Paliperidone].

Medizinische Monatsschrift fur Pharmazeuten 20060801

Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication.

Acta psychiatrica Scandinavica 20060701

Positive modulation of glutamatergic receptors potentiates the suppressive effects of antipsychotics on conditioned avoidance responding in rats.

Pharmacology, biochemistry, and behavior 20060601

Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes.

Archives of pharmacal research 20060601

[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations].

No to shinkei = Brain and nerve 20060601

Risperidone in the treatment of bipolar mania.

Neuropsychiatric disease and treatment 20060601

Optimization of the separation of some psychotropic drugs and their respective metabolites by liquid chromatography.

Journal of pharmaceutical and biomedical analysis 20060503

Intestinal uptake and biodistribution of novel polymeric micelles after oral administration.

Journal of controlled release : official journal of the Controlled Release Society 20060310

Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia.

Acta pharmacologica Sinica 20060301

A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.

The American journal of psychiatry 20060301

Liquid chromatography/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma.

Rapid communications in mass spectrometry : RCM 20060101

Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients.

Journal of clinical psychopharmacology 20051201

Plasma risperidone levels and clinical response in patients with first-episode psychosis.

Journal of clinical psychopharmacology 20051201

Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.

Clinical pharmacology and therapeutics 20051101

P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments.

Human psychopharmacology 20051001

Subtherapeutic risperidone serum concentrations in an adolescent during hemodialysis: a pharmacological puzzle.

Therapeutic drug monitoring 20051001

Risperidone plasma levels, clinical response and side-effects.

European archives of psychiatry and clinical neuroscience 20050801

Influence of age and gender on risperidone plasma concentrations.

Journal of psychopharmacology (Oxford, England) 20050701

Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition.

Clinical pharmacology and therapeutics 20050701

Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels.

The American journal of psychiatry 20050501

Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia.

The international journal of neuropsychopharmacology 20050301

Risperidone and breast-feeding.

Journal of psychopharmacology (Oxford, England) 20050301

Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.

International clinical psychopharmacology 20050301

Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service.

Therapeutic drug monitoring 20050201

The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model.

Drug metabolism and disposition: the biological fate of chemicals 20050101

Pharmacokinetic profile of long-acting injectable risperidone at steady-state: comparison with oral administration.

L'Encephale 20050101

The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein.

The international journal of neuropsychopharmacology 20041201

Identification and characterization of major degradation products of risperidone in bulk drug and pharmaceutical dosage forms.

Journal of pharmaceutical and biomedical analysis 20040921

A high-performance liquid chromatographic-atmospheric pressure chemical ionization-tandem mass spectrometric method for determination of risperidone and 9-hydroxyrisperidone in human plasma.

Journal of analytical toxicology 20040901

Plasma risperidone concentrations during combined treatment with sertraline.

Therapeutic drug monitoring 20040801

In vitro effects of risperidone and 9-hydroxy-risperidone on human platelet function, plasma coagulation, and fibrinolysis.

Clinical therapeutics 20040801

QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations.

Journal of psychopharmacology (Oxford, England) 20040601

Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes.

British journal of clinical pharmacology 20040501

Correlation between scores on Continuous Performance Test and plasma concentration for schizophrenic patients on risperidone.

Psychiatry and clinical neurosciences 20040401

Quantification of risperidone and 9-hydroxyrisperidone in plasma and saliva from adult and pediatric patients by liquid chromatography-mass spectrometry.

Journal of chromatography. A 20040213

Transfer of risperidone and 9-hydroxyrisperidone into human milk.

The Annals of pharmacotherapy 20040201

Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications.

Journal of child and adolescent psychopharmacology 20040101

Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone.

Therapeutic drug monitoring 20031201

Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia.

Therapeutic drug monitoring 20030601

Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers.

Clinical therapeutics 20030601

Effects of risperidone on psychometric and cognitive functions in healthy elderly volunteers.

Psychopharmacology 20030201

Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.

Journal of clinical pharmacology 20030201

Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography-tandem mass spectrometry.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030115

Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030105

Pharmacokinetic and safety assessments of galantamine and risperidone after the two drugs are administered alone and together.

Journal of clinical pharmacology 20021201

Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients.

Pharmacopsychiatry 20021101

A colloidal graphite-coated emitter for sheathless capillary electrophoresis/nanoelectrospray ionization mass spectrometry.

Analytical chemistry 20021015

Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy.

Synapse (New York, N.Y.) 20021001

Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in plasma after overdose.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020605

Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel.

The Journal of pharmacology and experimental therapeutics 20020501

Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.

The Journal of biological chemistry 20020419

In vivo and in vitro myocardial binding of risperidone and 9-hydroxyrisperidone.

Toxicology and applied pharmacology 20020415

The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients.

Pharmacopsychiatry 20020301

Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats.

Psychopharmacology 20020201

Risperidone and 9-hydroxyrisperidone concentrations are not dependent on age or creatinine clearance among elderly subjects.

Journal of geriatric psychiatry and neurology 20020101

Sequential changes in the plasma concentration of risperidone following intentional overdose.

Clinical neuropharmacology 20020101

Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes.

Drug metabolism and disposition: the biological fate of chemicals 20011001

Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine.

Therapeutic drug monitoring 20010601

Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels.

European psychiatry : the journal of the Association of European Psychiatrists 20010201

Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.

Psychopharmacology 20010101

Effects of two atypical neuroleptics, olanzapine and risperidone, on the function of the urinary bladder and the external urethral sphincter in anesthetized rats.

BMC pharmacology 20010101

Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study.

Neuropsychobiology 20010101

Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.

Psychopharmacology 19991201

Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.

The Journal of clinical psychiatry 19940501

144598-75-4 | 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-

Product Description

Properties

Literature

Related Products

Featured Products